BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 11842388)

  • 1. The role of rituximab and chemotherapy in aggressive B-cell lymphoma: a preliminary report of dose-adjusted EPOCH-R.
    Wilson WH; Gutierrez M; O'Connor P; Frankel S; Jaffe E; Chabner BA; Grossbard ML
    Semin Oncol; 2002 Feb; 29(1 Suppl 2):41-7. PubMed ID: 11842388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of rituximab and chemotherapy in aggressive B-cell lymphoma: A preliminary report of dose-adjusted EPOCH-R.
    Wilson WH; Gutierrez M; O'Connor P; Frankel S; Jaffe E; Chabner BA; Grossbard ML
    Semin Oncol; 2002 Feb; 29(1S2):41-47. PubMed ID: 28140091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study.
    Jermann M; Jost LM; Taverna Ch; Jacky E; Honegger HP; Betticher DC; Egli F; Kroner T; Stahel RA
    Ann Oncol; 2004 Mar; 15(3):511-6. PubMed ID: 14998858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma.
    Vose JM; Link BK; Grossbard ML; Czuczman M; Grillo-Lopez A; Gilman P; Lowe A; Kunkel LA; Fisher RI
    J Clin Oncol; 2001 Jan; 19(2):389-97. PubMed ID: 11208830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma.
    Vose JM; Link BK; Grossbard ML; Czuczman M; Grillo-Lopez A; Fisher RI
    Leuk Lymphoma; 2005 Nov; 46(11):1569-73. PubMed ID: 16236611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma.
    Mangel J; Buckstein R; Imrie K; Spaner D; Crump M; Tompkins K; Reis M; Perez-Ordonez B; Deodhare S; Romans R; Pennell N; Robinson JB; Hewitt K; Richardson P; Lima A; Pavlin P; Berinstein NL
    Semin Oncol; 2002 Feb; 29(1 Suppl 2):56-69. PubMed ID: 11842390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab in the treatment of diffuse large B-cell lymphomas.
    Coiffier B
    Semin Oncol; 2002 Feb; 29(1 Suppl 2):30-5. PubMed ID: 11842386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy.
    Czuczman MS; Grillo-López AJ; White CA; Saleh M; Gordon L; LoBuglio AF; Jonas C; Klippenstein D; Dallaire B; Varns C
    J Clin Oncol; 1999 Jan; 17(1):268-76. PubMed ID: 10458242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study.
    Zinzani PL; Stefoni V; Finolezzi E; Brusamolino E; Cabras MG; Chiappella A; Salvi F; Rossi A; Broccoli A; Martelli M
    Clin Lymphoma Myeloma; 2009 Oct; 9(5):381-5. PubMed ID: 19858058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma.
    Sparano JA; Lee JY; Kaplan LD; Levine AM; Ramos JC; Ambinder RF; Wachsman W; Aboulafia D; Noy A; Henry DH; Von Roenn J; Dezube BJ; Remick SC; Shah MH; Leichman L; Ratner L; Cesarman E; Chadburn A; Mitsuyasu R;
    Blood; 2010 Apr; 115(15):3008-16. PubMed ID: 20023215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy.
    Wilson WH; Grossbard ML; Pittaluga S; Cole D; Pearson D; Drbohlav N; Steinberg SM; Little RF; Janik J; Gutierrez M; Raffeld M; Staudt L; Cheson BD; Longo DL; Harris N; Jaffe ES; Chabner BA; Wittes R; Balis F
    Blood; 2002 Apr; 99(8):2685-93. PubMed ID: 11929754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aggressive lymphoma: improving treatment outcome with rituximab.
    Coiffier B; Pfreundschuh M; Stahel R; Vose J; Zinzani PL
    Anticancer Drugs; 2002 Nov; 13 Suppl 2():S43-50. PubMed ID: 12710590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CHOP plus rituximab chemoimmunotherapy of indolent B-cell lymphoma.
    Czuczman MS
    Semin Oncol; 1999 Oct; 26(5 Suppl 14):88-96. PubMed ID: 10561023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II trial of rituximab as adjuvant to intensive sequential chemotherapy in patients under 60 years with untreated poor-prognosis diffuse large B-cell lymphoma.
    Coso D; Sebban C; Boulat O; Biron P; Rey J; Aurran T; Chabannon C; Xerri L; Chetaille B; Esterni B; Ivanov V; Stoppa AM; Schiano de Collela JM; Gastaut JA; Maraninchi D; Bouabdallah R
    Bone Marrow Transplant; 2006 Aug; 38(3):217-22. PubMed ID: 16770316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1).
    Schmitz N; Nickelsen M; Ziepert M; Haenel M; Borchmann P; Schmidt C; Viardot A; Bentz M; Peter N; Ehninger G; Doelken G; Ruebe C; Truemper L; Rosenwald A; Pfreundschuh M; Loeffler M; Glass B;
    Lancet Oncol; 2012 Dec; 13(12):1250-9. PubMed ID: 23168367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype.
    Wilson WH; Jung SH; Porcu P; Hurd D; Johnson J; Martin SE; Czuczman M; Lai R; Said J; Chadburn A; Jones D; Dunleavy K; Canellos G; Zelenetz AD; Cheson BD; Hsi ED;
    Haematologica; 2012 May; 97(5):758-65. PubMed ID: 22133772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group.
    Purroy N; Bergua J; Gallur L; Prieto J; Lopez LA; Sancho JM; García-Marco JA; Castellví J; Montes-Moreno S; Batlle A; de Villambrosia SG; Carnicero F; Ferrando-Lamana L; Piris MA; Lopez A
    Br J Haematol; 2015 Apr; 169(2):188-98. PubMed ID: 25521006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH.
    Gutierrez M; Chabner BA; Pearson D; Steinberg SM; Jaffe ES; Cheson BD; Fojo A; Wilson WH
    J Clin Oncol; 2000 Nov; 18(21):3633-42. PubMed ID: 11054436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.